Evidence map›Paper›PMID 40132167›Full record

ArticleHepatology (Baltimore, Md.)2026

The Liver Transplant Comorbidity Index (LTCI): A composite index of ambulatory pre-LT factors to identify patients at increased risk of post-LT mortality.

Jennifer C Lai, Amy M Shui, Michele Molinari, Robert S Rahimi, Daniela P Ladner, Daniel R Ganger, Matthew Kappus, Elizabeth A King, Amit D Tevar, Michael L Volk and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Tumor burden and frailty: No association in liver transplantation candidates with hepatocellular carcinoma.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jennifer C LaiDepartment of Medicine, University of California, San Francisco, USA.
Amy M ShuiDepartment of Medicine, University of California, San Francisco, USA.
Michele MolinariDepartment of Surgery and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Robert S RahimiAnnette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Baylor Scott and White Health, Dallas, TX, USA.
Daniela P LadnerFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Daniel R GangerFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Matthew KappusDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Elizabeth A KingDepartment of Surgery, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Amit D TevarDepartment of Surgery and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Michael L VolkDepartment of Medicine, Baylor Scott & White Health, Dallas, TX, USA.
Andres Duarte-RojoFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-5377-9295
Elizabeth C VernaCenter for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA.

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
The spectrum of cognitive impairment including Alzheimer’s Disease and Related Dementias after liver transplantationR01AG059183 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer C. Lai · 2018 to 2026
$9.9M
Investigating the role of frailty on outcomes in acutely ill patients with cirrhosis undergoing liver transplantation in the acute care settingR01DK133527 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer C. Lai · 2023 to 2026
$2.9M
The Impact of Frailty on Liver Transplant Outcomes in Older Adults with Hepatocellular CarcinomaK24AG080021 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer C. Lai · 2023 to 2026
$755k
NIA NIH HHS K24 AG080021NIA NIH HHS R01 AG059183NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R01 DK133527
6 · The paper itself

Abstract

BACKGROUND AND

aimsFrailty is strongly associated with mortality after liver transplantation. However, national guidelines discourage its use as a sole reason to decline a patient for liver transplantation, as some frail patients have acceptable outcomes. We aimed to develop a composite index, the Liver Transplant Comorbidity Index (LTCI), integrating frailty and other comorbidities, as a risk factor for longer-term (3-year) posttransplant mortality. APPROACH AND

resultsThis 8-center prospective Functional Assessment in Liver Transplantation (FrAILT) Study included adult recipients of a primary deceased donor liver transplant from 2012 to 2022. Frailty was measured using the Liver Frailty Index (LFI ≥4.5=frail). Other candidate variables included demographics, laboratories, and comorbidities. Cox proportional hazards regression with best subset selection was used to identify risk factors of 3-year posttransplant death. The final model was selected based on Akaike Information Criterion and clinical pragmatism. Of 1472 liver transplant recipients, 290 (20%) were frail. Three-year posttransplant mortality was higher in frail versus non-frail patients (13% vs. 8%; p =0.03). The final LTCI included 5 variables: frailty, coronary artery disease, HCC, renal dysfunction, and diabetes. Three-year posttransplant mortality in low-risk, moderate-risk, and high-risk LTCI groups was 93%, 87%, and 80%, respectively. In multivariable analysis, after adjusting for donor factors (age and donation after circulatory death), both moderate-risk (HR: 2.23, 95% CI: 1.46-3.40; p <0.001) and high-risk (HR: 2.78, 95% CI: 1.67-4.64; p <0.001) status were associated with 3-year posttransplant mortality.

conclusionsThe LTCI, comprising 5 pretransplant clinical parameters, effectively identifies patients at increased risk of posttransplant mortality. By integrating frailty in the context of other comorbidities, the LTCI can help providers better weigh the relative transplant risks and benefits and standardize the selection of transplant candidates.

Indexed as

End Stage Liver DiseaseFrailtyLiver TransplantationAdultAgedComorbidityFemaleHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorscirrhosisfrailtyhCCrisk predictionsurgery

Identifiers

PMID40132167
PMCPMC12353854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.